|
|
Volumn 26, Issue 5, 2016, Pages 1365-1370
|
|
A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
Anti cancer; BET family; Bromodomain; CD28; Chemical biology; Immunosuppressant; Phenotypic drug discovery
|
|
Indexed keywords
ANTIMITOTIC AGENT;
ANTINEOPLASTIC AGENT;
BROMODOMAIN CONTAINING PROTEIN 2;
BROMODOMAIN CONTAINING PROTEIN 3;
BROMODOMAIN CONTAINING PROTEIN 4;
BROMODOMAIN INHIBITOR;
CD28 ANTIGEN;
DIAZEPINE DERIVATIVE;
IMMUNOSUPPRESSIVE AGENT;
PROTEIN;
THIENODIAZEPINE DERIVATIVE;
THIENOTRIAZOLODIAZEPINE DERIVATIVE;
UNCLASSIFIED DRUG;
AZEPINE DERIVATIVE;
BRD1 PROTEIN, HUMAN;
NUCLEAR PROTEIN;
THIENODIAZEPINE SUBSTANCE;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIGEN PRESENTING CELL;
ANTINEOPLASTIC ACTIVITY;
ANTIPROLIFERATIVE ACTIVITY;
ARTICLE;
BINDING ASSAY;
CANCER CELL LINE;
CELL STIMULATION;
CELL SURVIVAL;
CHEMICAL MODIFICATION;
CONTROLLED STUDY;
DRUG PROTEIN BINDING;
DRUG SCREENING;
DRUG SYNTHESIS;
EXPERIMENTAL ARTHRITIS;
HUMAN;
HUMAN CELL;
IC50;
IMMUNOREGULATION;
LYMPHOCYTE PROLIFERATION;
MOUSE;
NONHUMAN;
STRUCTURE ACTIVITY RELATION;
T LYMPHOCYTE;
TUMOR XENOGRAFT;
ANTAGONISTS AND INHIBITORS;
CELL PROLIFERATION;
CHEMICAL STRUCTURE;
CHEMISTRY;
CYTOLOGY;
DOSE RESPONSE;
DRUG DEVELOPMENT;
DRUG EFFECTS;
IMMUNOLOGY;
METABOLISM;
PHENOTYPE;
SYNTHESIS;
TUMOR CELL LINE;
ANTIGENS, CD28;
ANTINEOPLASTIC AGENTS;
AZEPINES;
CELL LINE, TUMOR;
CELL PROLIFERATION;
CELL SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DISCOVERY;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MOLECULAR STRUCTURE;
NUCLEAR PROTEINS;
PHENOTYPE;
STRUCTURE-ACTIVITY RELATIONSHIP;
T-LYMPHOCYTES;
|
|
EID: 84957850930
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2016.01.084 Document Type: Article |
|
Times cited : (10)
|
|
References (12)
|
